India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1 drugs show long-term promise. Sun Pharma is highlighted as a preferred domestic investment.
India's pharmaceutical sector is undergoing a strategic shift, moving beyond generics to focus on biosimilars, nutraceuticals, and consumer healthcare. This pivot, driven by innovation and contract manufacturing, is expected to unlock significant future profit opportunities.…
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.